about
Relapses in multiple sclerosis are associated with increased CD8+ T-cell mediated cytotoxicity in CSFMicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS).Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir.Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.An observational study of alemtuzumab following fingolimod for multiple sclerosis.High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis.Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.Upper Respiratory Infections and MRI Activity in Relapsing-Remitting Multiple Sclerosis.Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.[Neuromyelitis optica--important differential diagnosis to MS. Early treatment initiation crucial for the prognosis].A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS.Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.Processing in prefrontal cortex underlies tactile direction discrimination: An fMRI study of a patient with a traumatic spinal cord lesion.The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.MS risk genes are transcriptionally regulated in CSF leukocytes at relapse.Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis.A Sensitive Method for Detecting Peptide-specific CD4+ T Cell Responses in Peripheral Blood from Patients with Myasthenia Gravis.Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.Extreme stability of chitotriosidase in cerebrospinal fluid makes it a suitable marker for microglial activation in clinical trials.YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles.Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies.Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis.Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers.Serum levels of LIGHT in MSSoluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantroneSoluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantroneNeurofilament light protein and glial fibrillary acidic protein as biological markers in MSCerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosisCSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatmentFirst reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MSCerebrospinal fluid growth-associated protein 43 in multiple sclerosis
P50
Q28275615-98078711-6183-4499-91E0-1F874CD4081CQ34878368-DD9A1A48-4CE3-4CA7-AD66-17C858F0C7D8Q35166138-F6C96F8A-FEAE-43F1-981D-723BEBE057C8Q36839629-79E38C8B-2A23-43D0-B43E-E7F7F381F21AQ37579941-288AE3D8-A839-4B31-95B7-112D5633C1D7Q37689442-BF3C2712-7667-4CFF-909F-B2E6F72D2105Q39269762-98C7BB00-9C52-467E-9EB6-FFC0A8993AB4Q40047133-0279869D-41D4-45DC-96BF-A2EACF1330D9Q40597974-D6FB35AE-00A7-4B88-AAFB-9D6F1E23FF37Q40821569-346FB007-2B24-43CF-9073-753A0070A9DDQ42752537-6BD5F62C-B9F0-4503-97C4-BA31624B09E8Q43847866-0986A967-9BB5-4BCD-B1A4-09433A5124B0Q44028578-D4A0E488-B9F4-4241-B325-323373B926C2Q44291906-5C76153A-A1D6-42A6-BDF3-145F25C3CB45Q44342102-3858C25E-F799-48F9-A6E0-4BFD845D4828Q45817831-78A65961-845A-46AA-83A6-E7084F632500Q46157365-B00409ED-2337-4677-AA91-3A07F3402099Q46908307-E976E908-4CEB-4733-89D2-1188570A0CF6Q46910370-8505A933-9302-4E59-9271-90325AD6610AQ47144073-67EAEE2D-1A65-447E-81DD-9E71E679BA7AQ48444418-F1FDA4A0-F8CF-4F34-BACA-66E07C9DD89BQ48859275-B89FA3E4-D9A9-4015-B404-EDED84CFB6BEQ48934460-06961C06-9B29-452D-B43F-9387A2D506E0Q50597243-B4572F0D-28E0-41B6-B9DC-8889EE3C20E5Q50965805-759A9CD1-CC8A-46AA-8473-0AE6F0762B58Q51068605-A19B8BF4-6F5E-4186-B63C-CBDD03F8DA5DQ51156844-979F61B0-7C4A-4FD2-84DA-1DC1402CC7BCQ51167002-C1D18043-10A3-459B-A58A-C946BE38B1FAQ51359685-757E98A2-889A-4B2E-B21B-BCB0C4D659A4Q52149906-2D389AE3-FE9A-4A03-ADD9-8D3E7CFC9566Q53624114-41659AE2-2B78-4559-9BA2-33ECAF228047Q55402326-CE6B0E44-9C9E-48D4-998F-FB61054E4136Q57224216-247A0247-130C-4BDF-93E3-DE770DE535DFQ61699068-0E9929A5-C3E2-4261-8BCE-1FF232C9E266Q61699071-A5119EF9-8810-43CA-BE78-28D39C46363EQ75205821-090D5ECE-450E-47A1-8B4D-0538DA3D27DFQ85194843-36FC9FF4-D851-46F9-8CE2-2B5B8F5F97D7Q87383521-875C2D03-012D-4EA3-97E2-21258B15866DQ87482651-587FEF41-B071-4F94-8CF1-ECF60C87E5D8Q91386535-AC444BDE-4634-4D03-84C2-7D5FF65A56FB
P50
description
Zweeds onderzoeker
@nl
forsker
@nb
hulumtues
@sq
researcher
@en
հետազոտող
@hy
name
Clas Malmeström
@ast
Clas Malmeström
@da
Clas Malmeström
@de
Clas Malmeström
@en
Clas Malmeström
@es
Clas Malmeström
@fr
Clas Malmeström
@nb
Clas Malmeström
@nl
Clas Malmeström
@nn
Clas Malmeström
@sl
type
label
Clas Malmeström
@ast
Clas Malmeström
@da
Clas Malmeström
@de
Clas Malmeström
@en
Clas Malmeström
@es
Clas Malmeström
@fr
Clas Malmeström
@nb
Clas Malmeström
@nl
Clas Malmeström
@nn
Clas Malmeström
@sl
prefLabel
Clas Malmeström
@ast
Clas Malmeström
@da
Clas Malmeström
@de
Clas Malmeström
@en
Clas Malmeström
@es
Clas Malmeström
@fr
Clas Malmeström
@nb
Clas Malmeström
@nl
Clas Malmeström
@nn
Clas Malmeström
@sl
P1053
A-8749-2012
P106
P21
P27
P31
P3829
P496
0000-0003-2477-0088